|
|
| General |
| Study Status |
Ongoing |
Application Number /
Requirement Number |
P140031 S125/ PAS001 |
| Date Original Protocol Accepted |
05/13/2021
|
| Date Current Protocol Accepted |
05/13/2021
|
| Study Name |
SAPIEN 3 & SAPIEN 3 Ultra Mitral ValveInRing Surv
|
| Device Name |
SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve System
|
| General Study Protocol Parameters |
| Study Design |
Active Surveillance
|
| Data Source |
External Registry
|
| Comparison Group |
Historical Control
|
| Analysis Type |
Descriptive
|
| Detailed Study Protocol Parameters |
| Study Objectives |
Comprehensive/linked/registry-based surveillance. The objective of the surveillance is to continue to monitor the performance of the Edwards SAPIEN 3 and SAPIEN 3 Ultra THV System in the real-world setting.
|
| Study Population |
Patients with symptomatic heart disease due to failing of a native mitral valve with an annuloplasty ring who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality greater than or equal to 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).
|
| Sample Size |
All consecutive patients treated within the first 5 years after the PMA approval that are entered into the TVT Registry.
|
| Key Study Endpoints |
(1) device success (intra-procedure); (2) all-cause mortality, all stroke, life-threatening/major bleeding, new requirement for dialysis, peri-procedural myocardial infarction, and repeat procedure for valve-related dysfunction (surgical or interventional therapy) at 30 days and 12 months; and (3) neurological (non-stroke), vascular complications, and quality of life (KCCQ) outcomes at 30 days and 12 months.
|
| Follow-up Visits and Length of Follow-up |
1 year
|
| Interim or Final Data Summary |
| Interim Results |
Safety Results:
Procedural Outcomes: Device implanted successfully: 91.2% (343/376)
Safety outcomes at 1 Year:
All-cause death: 30.8%
Cardiac death: 14.5%
All stroke: 2.6%
Mitral valve reintervention: 8.0%
Life threatening/major bleeding: 6.9%
New requirement for dialysis: 5.6%
Vascular complications: 5.6%
Effectiveness outcomes at 1 Year:
Improvement from baseline in NYHA function classification: 70.3% KCCQ Overall Summary Score change from baseline: 28.4
Effective Orifice Area: 1.82 cm2
Mean Gradient: 7.8 mmHg
Moderate or greater total mitral regurgitation: 2.3%
Moderate or greater paravalvular mitral regurgitation: 3.0%
|
| Actual Number of Patients Enrolled |
376 patients (Attempted Implant); 373 patients (valve implanted)
|
| Actual Number of Sites Enrolled |
183
|
| Patient Follow-up Rate |
At 1 year, subject status was known in 76.9% of subjects (188 visits completed, 96 dead, 5 visit not completed but alive)
|
